Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1246347.RA25KfgSfNhYpst45e6G_6WyOmrbl_-Y2-Fn7ed9RfBrM130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1246347.RA25KfgSfNhYpst45e6G_6WyOmrbl_-Y2-Fn7ed9RfBrM130_assertion type Assertion NP1246347.RA25KfgSfNhYpst45e6G_6WyOmrbl_-Y2-Fn7ed9RfBrM130_head.
- NP1246347.RA25KfgSfNhYpst45e6G_6WyOmrbl_-Y2-Fn7ed9RfBrM130_assertion description "[Our findings strongly support the clinical testing of combined hormone antagonist-low-level HSP90 inhibitor regimens in the treatment of metastatic estrogen receptor-positive breast cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1246347.RA25KfgSfNhYpst45e6G_6WyOmrbl_-Y2-Fn7ed9RfBrM130_provenance.
- NP1246347.RA25KfgSfNhYpst45e6G_6WyOmrbl_-Y2-Fn7ed9RfBrM130_assertion evidence source_evidence_literature NP1246347.RA25KfgSfNhYpst45e6G_6WyOmrbl_-Y2-Fn7ed9RfBrM130_provenance.
- NP1246347.RA25KfgSfNhYpst45e6G_6WyOmrbl_-Y2-Fn7ed9RfBrM130_assertion SIO_000772 25489079 NP1246347.RA25KfgSfNhYpst45e6G_6WyOmrbl_-Y2-Fn7ed9RfBrM130_provenance.
- NP1246347.RA25KfgSfNhYpst45e6G_6WyOmrbl_-Y2-Fn7ed9RfBrM130_assertion wasDerivedFrom befree-2016 NP1246347.RA25KfgSfNhYpst45e6G_6WyOmrbl_-Y2-Fn7ed9RfBrM130_provenance.
- NP1246347.RA25KfgSfNhYpst45e6G_6WyOmrbl_-Y2-Fn7ed9RfBrM130_assertion wasGeneratedBy ECO_0000203 NP1246347.RA25KfgSfNhYpst45e6G_6WyOmrbl_-Y2-Fn7ed9RfBrM130_provenance.